Literature DB >> 20227484

Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms.

Abhishek Chandra1, Gary P Wormser, Mark S Klempner, Richard P Trevino, Mary K Crow, Norman Latov, Armin Alaedini.   

Abstract

Some Lyme disease patients report debilitating chronic symptoms of pain, fatigue, and cognitive deficits despite recommended courses of antibiotic treatment. The mechanisms responsible for these symptoms, collectively referred to as post-Lyme disease syndrome (PLS) or chronic Lyme disease, remain unclear. We investigated the presence of immune system abnormalities in PLS by assessing the levels of antibodies to neural proteins in patients and controls. Serum samples from PLS patients, post-Lyme disease healthy individuals, patients with systemic lupus erythematosus, and normal healthy individuals were analyzed for anti-neural antibodies by immunoblotting and immunohistochemistry. Anti-neural antibody reactivity was found to be significantly higher in the PLS group than in the post-Lyme healthy (p<0.01) and normal healthy (p<0.01) groups. The observed heightened antibody reactivity in PLS patients could not be attributed solely to the presence of cross-reactive anti-borrelia antibodies, as the borrelial seronegative patients also exhibited elevated anti-neural antibody levels. Immunohistochemical analysis of PLS serum antibody activity demonstrated binding to cells in the central and peripheral nervous systems. The results provide evidence for the existence of a differential immune system response in PLS, offering new clues about the etiopathogenesis of the disease that may prove useful in devising more effective treatment strategies. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227484      PMCID: PMC2897967          DOI: 10.1016/j.bbi.2010.03.002

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  37 in total

Review 1.  Lyme disease.

Authors:  A C Steere
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

Review 2.  Losing your nerves? Maybe it's the antibodies.

Authors:  Betty Diamond; Patricio T Huerta; Paola Mina-Osorio; Czeslawa Kowal; Bruce T Volpe
Journal:  Nat Rev Immunol       Date:  2009-06       Impact factor: 53.106

3.  High resolution two-dimensional electrophoresis of proteins.

Authors:  P H O'Farrell
Journal:  J Biol Chem       Date:  1975-05-25       Impact factor: 5.157

4.  Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease.

Authors:  M S Klempner; L T Hu; J Evans; C H Schmid; G M Johnson; R P Trevino; D Norton; L Levy; D Wall; J McCall; M Kosinski; A Weinstein
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

5.  Multiple cross-reactive self-ligands for Borrelia burgdorferi-specific HLA-DR4-restricted T cells.

Authors:  B Maier; M Molinger; A P Cope; L Fugger; J Schneider-Mergener; G Sønderstrup; T Kamradt; A Kramer
Journal:  Eur J Immunol       Date:  2000-02       Impact factor: 5.532

6.  Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer.

Authors:  Y Shoenfeld; A Nahum; A D Korczyn; M Dano; R Rabinowitz; O Beilin; C G Pick; L Leider-Trejo; L Kalashnikova; M Blank; J Chapman
Journal:  Lupus       Date:  2003       Impact factor: 2.911

Review 7.  Has the yo-yo stopped? An assessment of human protein-coding gene number.

Authors:  Christopher Southan
Journal:  Proteomics       Date:  2004-06       Impact factor: 3.984

Review 8.  Lyme borreliosis.

Authors:  Gerold Stanek; Franc Strle
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

9.  Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial.

Authors:  L B Krupp; L G Hyman; R Grimson; P K Coyle; P Melville; S Ahnn; R Dattwyler; B Chandler
Journal:  Neurology       Date:  2003-06-24       Impact factor: 9.910

10.  Molecular analysis of the human autoantibody response to alpha-fodrin in Sjögren's syndrome reveals novel apoptosis-induced specificity.

Authors:  Toshiaki Maruyama; Ichiro Saito; Yoshio Hayashi; Elizabeth Kompfner; Robert I Fox; Dennis R Burton; Henrik J Ditzel
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

View more
  28 in total

1.  CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study.

Authors:  John N Aucott; Mark J Soloski; Alison W Rebman; Lauren A Crowder; Lauren J Lahey; Catriona A Wagner; William H Robinson; Kathleen T Bechtold
Journal:  Clin Vaccine Immunol       Date:  2016-09-06

2.  Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory Lyme arthritis.

Authors:  Jameson T Crowley; Klemen Strle; Elise E Drouin; Annalisa Pianta; Sheila L Arvikar; Qi Wang; Catherine E Costello; Allen C Steere
Journal:  J Autoimmun       Date:  2016-02-26       Impact factor: 7.094

Review 3.  Lyme borreliosis.

Authors:  Allen C Steere; Franc Strle; Gary P Wormser; Linden T Hu; John A Branda; Joppe W R Hovius; Xin Li; Paul S Mead
Journal:  Nat Rev Dis Primers       Date:  2016-12-15       Impact factor: 52.329

4.  Expression of C-Reactive Protein and Serum Amyloid A in Early to Late Manifestations of Lyme Disease.

Authors:  Melanie Uhde; Mary Ajamian; Xueting Li; Gary P Wormser; Adriana Marques; Armin Alaedini
Journal:  Clin Infect Dis       Date:  2016-09-01       Impact factor: 9.079

5.  Posttreatment Symptoms in Lyme Borreliosis.

Authors:  Klemen Strle; Franc Strle
Journal:  Clin Infect Dis       Date:  2020-12-15       Impact factor: 9.079

6.  Increased IFNα activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits.

Authors:  Elzbieta Jacek; Brian A Fallon; Abhishek Chandra; Mary K Crow; Gary P Wormser; Armin Alaedini
Journal:  J Neuroimmunol       Date:  2012-11-08       Impact factor: 3.478

7.  Epitope-Specific Evolution of Human B Cell Responses to Borrelia burgdorferi VlsE Protein from Early to Late Stages of Lyme Disease.

Authors:  Elzbieta Jacek; Kevin S Tang; Lars Komorowski; Mary Ajamian; Christian Probst; Brian Stevenson; Gary P Wormser; Adriana R Marques; Armin Alaedini
Journal:  J Immunol       Date:  2015-12-30       Impact factor: 5.422

8.  Elevated levels of IL-23 in a subset of patients with post-lyme disease symptoms following erythema migrans.

Authors:  Klemen Strle; Daša Stupica; Elise E Drouin; Allen C Steere; Franc Strle
Journal:  Clin Infect Dis       Date:  2013-11-11       Impact factor: 9.079

9.  A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease.

Authors:  Elise E Drouin; Robert J Seward; Klemen Strle; Gail McHugh; Kianoosh Katchar; Diana Londoño; Chunxiang Yao; Catherine E Costello; Allen C Steere
Journal:  Arthritis Rheum       Date:  2013-01

10.  Association of immune response to endothelial cell growth factor with early disseminated and late manifestations of Lyme disease but not posttreatment Lyme disease syndrome.

Authors:  Kevin S Tang; Mark S Klempner; Gary P Wormser; Adriana R Marques; Armin Alaedini
Journal:  Clin Infect Dis       Date:  2015-07-28       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.